TC
KYMR icon

Truvestments Capital’s Kymera Therapeutics KYMR Stock Holding History

Truvestments Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.7K Sell
213
-61
-22% -$4.83K ﹤0.01% 669
2025
Q4 		$21.3K Hold
274
– – ﹤0.01% 579
2025
Q3 		$15.5K Sell
274
-44
-14% -$1.98K ﹤0.01% 644
2025
Q2 		$13.9K Hold
318
– – ﹤0.01% 602
2025
Q1 		$8.7K Sell
318
-33
-9% -$1.2K ﹤0.01% 678
2024
Q4 		$14.1K Buy
351
+54
+18% +$2.44K ﹤0.01% 545
2024
Q3 		$14.1K Buy
+297
New +$13.1K ﹤0.01% 533
2024
Q2 		– Sell
-163
Closed -$6.55K – 472
2024
Q1 		$6.55K Hold
163
– – ﹤0.01% 530
2023
Q4 		$4.15K Hold
163
– – ﹤0.01% 615
2023
Q3 		$2.27K Hold
163
– – ﹤0.01% 580
2023
Q2 		$3.75K Hold
163
– – ﹤0.01% 553
2023
Q1 		$4.83K Buy
163
+104
+176% +$3.35K ﹤0.01% 515
2022
Q4 		$1.47K Hold
59
– – ﹤0.01% 780
2022
Q3 		$1K Hold
59
– – ﹤0.01% 591
2022
Q2 		$1K Buy
+59
New +$1.38K ﹤0.01% 605

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Truvestments Capital's KYMR Position: Q1 2026 in Review

Truvestments Capital reduced its Kymera Therapeutics (KYMR) stake by 22% in Q1 2026, selling an estimated $4.83K and leaving 213 shares worth $17.7K. The position accounts for ﹤0.01% of the portfolio, ranked #669.

Truvestments Capital first reported a position in KYMR in Q2 2022 and has held it in 15 quarters since. The position peaked at $21.3K in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Truvestments Capital held 213 shares of Kymera Therapeutics worth $17.7K as of Q1 2026.
  • Truvestments Capital sold 61 Kymera Therapeutics shares in Q1 2026, an estimated $4.83K.
  • Kymera Therapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q1 2026, its #669 holding.
  • Truvestments Capital first reported a position in Kymera Therapeutics in Q2 2022 and has held it in 15 quarters since.
  • Truvestments Capital's Kymera Therapeutics position peaked at $21.3K in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.